The General Partnership (TheGP) is a San Francisco-based venture capital firm that combines capital investment with a 'sweat equity' model, embedding a team of 25+ full-time engineers, recruiters, designers, and sales leaders into portfolio companies. The firm invests at the formation (pre-seed/seed) and breakout (series A) stages across enterprise software, fintech, developer tools, cybersecurity, healthcare, and AI.
Founded —
Type Venture capital 0 No funds on record yet.
$1M $100K – $5M San Francisco Bay Area $1M $100K – $5M San Francisco Bay Area $1M $100K – $5M San Francisco Bay Area $1M $100K – $5M San Francisco, California $50K $10K – $100K New York, New York — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – —
SHOW MORE
$9M 2026-04-13 Ultralight Y Combinator , GSBackers , The General Partnership , Emerson Collective , Wisdom Ventures , Anthemis $— 2026-02-11 Meridian The General Partnership $— 2026 Ultralight The General Partnership $24M 2025-09-24 Manas General Catalyst , Greylock Partners , Mosaic Ventures , The General Partnership , Wisdom Ventures , Westbound Equity Partners $10M 2025-09-08 Cassidy AI HOF Capital , The General Partnership $— 2025-07-30 Runloop The General Partnership $40M 2025-04-03 Thatch General Catalyst , The General Partnership , Index Ventures , AMD Ventures , SemperVirens Venture Capital , Julie Yoo , Alex Tran , Phin Barnes $— 2025-04-02 SchoolAI The General Partnership $52M 2025-03-18 Graphite Accel , The General Partnership , Rama Sekhar , Peter Levine $— 2025 Cassidy AI The General Partnership $— 2025 TurbineOne Bessemer Venture Partners , The General Partnership $38M 2024-09-05 Thatch General Catalyst , The General Partnership , Index Ventures , Avid Ventures , SemperVirens Venture Capital , Julie Yoo , Alex Tran , Phin Barnes $15M 2024-07-18 Momento Bain Capital , The General Partnership $— 2024-07-17 Aven Founders Fund , General Catalyst , Caffeinated Capital , Khosla Ventures , Electric Capital , The General Partnership $— 2024-04-18 Clazar The General Partnership $— 2024 EarthFast The General Partnership $— 2023-12-12 Laza Medical The General Partnership $— 2023-11-21 Supira Medical The General Partnership $— 2023-10-03 Akura Medical The General Partnership $50M 2023-07-11 Collective General Catalyst , Inovia Capital , The General Partnership , Gradient Ventures , QED Investors , Expa , Niko Bonatsos , Darian Shirazi $— 2023-02-09 Tioga Cardiovascular The General Partnership $— 2023 Clazar The General Partnership $52M 2022-09-20 Sardine The General Partnership , Alex Immerman , Angela Strange , Eric Schmidt $30M 2022-08-10 Finix Bain Capital , Franklin Templeton , Acrew Capital , Precursor Ventures , The General Partnership , Lightspeed , Bain Capital Ventures , Altos Ventures Management, Inc. $13M 2022-05-02 Switchboard Sequoia , The General Partnership , XYZ Venture Capital , Spark Capital , Leo Capital $— 2022-04-29 Adona Medical The General Partnership $50M 2015 Collective Gradient Ventures , The General Partnership $— Unknown date Dexa.ai The General Partnership $— Unknown date Olto The General Partnership $— Unknown date Defakto The General Partnership $— Unknown date Pixeltable The General Partnership $20M Unknown date Minerva Y Combinator , 8VC , The General Partnership , NBA Investments $25M Unknown date Stainless Sequoia , The General Partnership , Felicis , MongoDB Ventures $35M Unknown date Multiplier Holdings Lightspeed , The General Partnership , Ribbit Capital , Phoenix Court Group $40M Unknown date Thatch Health General Catalyst , Andreessen Horowitz , The General Partnership , Index Ventures , SemperVirens Venture Capital $6M Unknown date Dynaboard General Catalyst , The House Fund , Floodgate Fund , Abstract Ventures , Dorm Room Fund , The General Partnership $15M Unknown date Momento Bain Capital , Y Combinator , The General Partnership , Bain Capital Ventures $— Unknown date Aven Caffeinated Capital , Electric Capital , Khosla Ventures , Founders Fund , General Catalyst , The General Partnership $10M 2025-09-08 Cassidy HOF Capital , The General Partnership $— 2025-07-30 Runloop AI The General Partnership $— Unknown date Integral Privacy Technologies The General Partnership
SHOW MORE
team@apexlogos.ai · 28 minutes ago
Match research 2026-10-06 / TheGeneralPartnership / sha256:a7d928670ae232bf2df12dc61caa08413f3e87b78c07605e863fe1dc14448e53 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
| **Manas AI** | Develops science-based foundational models integrating chemistry, physics and biology for therapeutic discovery and development; scientifically intensive AI plus biopharmaceutical R&D supports a deep-tech classification. The company's [official 2025-09-23 announcement](https://manasai.co/news/manas-ai-announces-26m-seed-extension-and-the-appointment-of-ujjwal-singh-as-co-founder-and-chief-technology-officer ) confirms closing a **USD 26 million seed extension** and names The General Partnership among participants. Its [current official site](https://manasai.co/ ) describes small molecules, antibodies and siRNA discovery modalities. | Participation, not verified lead role; check undisclosed. The USD 24.6 million January 2025 initial seed was separately led by General Catalyst and Reid Hoffman; it is not the September extension amount. This is drug discovery, not verified neural-device investment. “Neuro-symbolic AI” describes an AI method and does not establish neurotechnology. |
## Neurotech findings and excluded/uncertain leads
**No verified neurotech investment found in the sources checked.** Checks included the exact snapshot, NFX firm/Phin Barnes pages, the current official firm site and strategy/case-study pages, Manas' official materials, the medical-device funding sources below, and searches for the firm with neurotech, neurotechnology, neuroscience, brain and Neuralink. This is a bounded public-source finding, not a claim the firm has never invested in the sector. General AI, Manas' neuro-symbolic AI, healthcare benefits software such as Thatch, and cardiovascular devices do not by themselves meet a direct neural/brain technology definition.
The following baseline medical-device rows are **not verified TheGP investments**. Four directly readable investee-issued releases name a different firm, The Capital Partnership (TCP), rather than The General Partnership. The similarity of the names suggests an entity-resolution error; it does not prove TheGP could never have made another, undisclosed investment in these businesses.
| Snapshot company / claimed round | Source finding | Source date / URL |
| --- | --- | --- |
| Laza Medical; USD 36m Series A | Cardiac robotic imaging technology; release says led by The Capital Partnership, with GE HealthCare, PA MedTech VC, Unorthodox Ventures and Dara Holdings. TheGP not named. | [Laza company release, 2023-12-12](https://www.prnewswire.com/news-releases/laza-medical-inc-a-shifamed-portfolio-company-closes-36m-in-series-a-financing-302012751.html ) |
| Supira Medical; USD 40m Series D | Percutaneous ventricular assist device; release says Cormorant and The Capital Partnership led, with other named investors. TheGP not named. | [Supira company release, 2023-11-21](https://www.prnewswire.com/news-releases/supira-medical-inc-a-shifamed-portfolio-company-receives-fda-breakthrough-device-designation-as-the-company-closed-40m-in-series-d-financing-301994278.html ) |
| Akura Medical; USD 35m Series B | Mechanical thrombectomy platform; release says The Capital Partnership and Cormorant led. TheGP not named. | [Akura company release, 2023-10-03](https://www.prnewswire.com/news-releases/akura-medical-a-shifamed-portfolio-company-closes-35m-in-series-b-financing-301945091.html ) |
| Tioga Cardiovascular; USD 30m Series C | Transseptal mitral valve replacement; release says first closing led by Cormorant with participation from The Capital Partnership and other investors. TheGP not named. | [Tioga company release, 2023-02-09](https://www.prnewswire.com/news-releases/tioga-cardiovascular-a-shifamed-portfolio-company-closes-30m-in-series-c-financing-301742478.html ) |
| Adona Medical; USD 37.5m Series B | Heart-failure management technology; supporting reporting names Cormorant and The Capital Partnership as leaders. Primary PR URL initially opened but repeated fetches failed/403, so this row has a weaker direct-access audit than the four above. | Snapshot primary lead: [company PR, 2022-04-29](https://www.prnewswire.com/news-releases/adona-medical-a-shifamed-portfolio-company-secures-37-5m-in-series-b-financing-301536096.html ); supporting [BioSpace reporting, May 2022](https://www.biospace.com/money-on-the-move-april-showers-bring-may-flowers-and-funding ) and [Gaebler round record, 2022-04-29](https://www.gaebler.com/VC-Funding-974D40AC-AD1D-49BD-A86C-CE3CB86B1F0E-Adona-Medical-04-29-2022 ) |
Momento, Pixeltable, Runloop and Integral are technology/infrastructure leads in the snapshot. They have not been upgraded here into verified scientifically intensive deep-tech examples solely because they use AI, handle data or provide developer infrastructure. Other snapshot SaaS/fintech investments are outside the requested deep-tech/neurotech evidence focus.
## Conflicts, gaps and notes for later Adex review
1. Review the five medical-device participation records for confusion with The Capital Partnership. Their cited funding announcements do not substantiate TheGP attribution. Preserve evidence and route any later correction through a separate authorized review; no database edit was performed here.
2. Review the Manas row: the snapshot dates it 2025-09-24 but assigns USD 24.6 million and links a January 2025 Axios article. The official extension is dated **2025-09-23 and USD 26 million**, whereas USD 24.6 million belongs to the earlier seed led by General Catalyst/Reid Hoffman. Do not convert either full-round total into TheGP's personal contribution.
3. Deduplicate apparent aliases and repeated deals before interpreting portfolio counts: Ultralight, Runloop/Runloop AI, Cassidy/Cassidy AI, Thatch/Thatch Health and Momento recur in the snapshot. The 2015 Collective USD 50 million entry conflicts with a 2023-07-11 row for the same apparent deal and predates the 2018 predecessor; verify independently rather than accepting it.
4. Update review evidence for Fund II and milestone-based breakout strategy. NFX's USD 240 million “current” size and USD 100k–5m partner range should retain historical/directory caveats; current firmwide checks are USD 1–30m+.
5. Fund-specific allocations, TheGP's check amounts in the named rounds, portfolio ownership percentages, current total AUM, legal inception dates and exhaustive latest portfolio coverage remain unverified. Firm service relationships can produce equity without a cash investment, and prior jobs/partner history must not be treated as firm investments.
6. The absence of verified neurotech is limited to public sources checked. A direct question to the firm or further portfolio audit could reveal relevant unpublished exposure; no outreach was authorized or performed.
All undated sources cited above were accessed 2026-10-06. This file is research for later Adex review only; Adex/database, MCP Patch and commits were not used to make changes. SHOW MORE
team@apexlogos.ai · 28 minutes ago
Match research 2026-10-06 / TheGeneralPartnership / sha256:a7d928670ae232bf2df12dc61caa08413f3e87b78c07605e863fe1dc14448e53 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# The General Partnership
- Exact Adex ID: `TheGeneralPartnership`
- Canonical Adex URL: https://adex.page/firms/TheGeneralPartnership
- Research date / source access date: 2026-10-06
- Research status: complete for this research pass; remaining verification gaps are identified below.
## Summary and identity
The General Partnership (TheGP) is a San Francisco venture firm that combines cash investments with engineering, recruiting and go-to-market work exchanged for equity. Its current strategy covers pre-seed/seed formation and post-product-market-fit breakout companies, including later financing rounds. Its latest-known publicly confirmed fund close is **TheGP II, USD 300 million, announced 2024-06-27**. Verified deep-tech examples are TurbineOne (edge AI for defense) and Manas AI (science-based foundational models for drug discovery). **No verified neurotech investment found in the sources checked.** Several medical-device investments in the Adex snapshot appear to confuse this firm with **The Capital Partnership (TCP)** and should not be counted as verified TheGP investments. [Official about page](https://www.thegp.com/about ), [official fund announcement, 2024-06-27](https://www.thegp.com/writing/new-fund-same-mission ).
The predecessor, Sweat Equity Ventures (SEV), began in 2018; the firm adopted the TheGP identity and added institutional investment capital in 2022. This explains differences between 2018 and 2022 foundation dates without asserting they refer to identical legal-entity formation events. The current site gives the address 447 Battery Street, Suite 200, San Francisco, CA 94111. [Official inaugural fund announcement, 2022-06-07](https://www.thegp.com/writing/redefining-value-in-vc-working-for-equity-accelerating-with-capital ), [homepage](https://www.thegp.com/ ).
## Adex and NFX starting evidence
The saved read-only MCP snapshot `data/research/_sources/TheGeneralPartnership.adex.json`, retrieved 2026-10-06 at 19:29:32 UTC, contains the exact ID and URL above. It describes the capital-plus-work model, a team of 25+ and formation/pre-seed/seed and breakout/Series A activity across enterprise software, fintech, developer tools, cybersecurity, healthcare and AI. Investor check minimum/maximum/sweet spot are null. Snapshot evidence points to the official site, NFX Signal and Goldi; these baseline descriptions and transaction rows are research leads, not independently verified facts. The 25+ headcount was not freshly verified.
Relevant baseline investments include TurbineOne, Manas, Laza Medical, Supira Medical, Akura Medical, Tioga Cardiovascular, Adona Medical, Momento, Pixeltable, Runloop, Integral Privacy Technologies, Cassidy and Dexa. The snapshot includes duplicate/alias rows and mixes round totals with investor `amount` fields; an amount on a participation record is not evidence that TheGP invested that entire sum. See specific conflicts below.
[The NFX firm page](https://signal.nfx.com/firms/the-general-partnership ) was directly read, rather than relying only on search results. It lists New York, New York, founded 2018, and a general formation/growth and go-to-market support description. The current official San Francisco address is stronger evidence for the firm's present base; NFX's New York label may reflect an office/profile convention rather than headquarters. [Phin Barnes' NFX profile](https://signal.nfx.com/investors/phin-barnes ) was also directly read: current affiliation The General Partnership, investment range USD 100,000–5 million, sweet spot USD 1.5 million and “Current Fund Size” USD 240 million. These are undated directory claims accessed 2026-10-06. The fund-size entry is stale relative to the 2024 official Fund II close, and the partner range should not override current firmwide checks. Partner investment counts and records can span prior affiliations; they are not automatically TheGP transactions.
## Fund size and investment stages
| Vehicle / metric | Amount and status | Dated supporting source / caveat |
| --- | --- | --- |
| Inaugural institutional fund | USD 240 million; announced as raised institutional fund, not merely a fundraising target | [TheGP, 2022-06-07](https://www.thegp.com/writing/redefining-value-in-vc-working-for-equity-accelerating-with-capital ). This was the first outside institutional capital raise following SEV's evolution into TheGP. |
| TheGP II | USD 300 million; explicitly closed and oversubscribed | [TheGP, 2024-06-27](https://www.thegp.com/writing/new-fund-same-mission ); corroborating [Axios, 2024-06-27](https://www.axios.com/2024/06/27/sweat-equity-the-general-partnership-second-fund ). Latest-known confirmed fund close in this pass, not a guarantee no undisclosed/newer vehicle exists. |
| Current firmwide typical check | USD 1–30 million+ | [Official about page](https://www.thegp.com/about ), undated, accessed 2026-10-06. Check size, not fund size or AUM. |
The two announced funds sum arithmetically to USD 540 million, but that is **not a verified current AUM figure**, deployable balance or single fund size. A search for later funds, including Fund III and 2025–2026 announcements, found no newer official close. Secondary regulatory mirrors were not used as independently verified AUM evidence.
The current [official about page](https://www.thegp.com/about ) explicitly defines formation as pre-seed and seed, often leading those rounds, with capital reserved for company growth. Breakout means companies past product-market fit approaching substantial growth, with operational work and later cash financing as appropriate; it is **not restricted to Series A**. The [strategy essay](https://www.thegp.com/writing/how-we-partner-at-thegp ) historically described formation checks of USD 1–5 million. Later Series B activity at TurbineOne demonstrates historical transactions beyond Series A, while the current strategy remains defined by business development milestones.
The [Investor in Residence announcement, 2026-02-24](https://www.thegp.com/writing/introducing-thegps-investor-in-residence-program ) introduces cybersecurity domain expertise and says the firm is exploring AI research, healthcare, energy, bio, crypto and robotics. Exploration is not proof of completed investments in every category. Investors in Residence may continue managing their own funds or angel investing, so their outside investments also require separate attribution.
## Verified previous deep-tech investments
| Company | Technology rationale and investment evidence | Attribution / limitations |
| --- | --- | --- |
| **TurbineOne** | Frontline Perception System processes sensor feeds into threat alerts at the tactical edge, including disconnected environments. This is applied edge AI/ML and sensor perception with demanding defense deployment constraints; deep-tech classification is an analyst judgment, not simply a software-sector label. TheGP's [official case study](https://www.thegp.com/portfolio/turbineone ) says it partnered in 2021, helped incubate the company and provided talent, engineering, GTM and capital. A **USD 36 million Series B announced 2025-05-14 was led by The General Partnership**. [Corrected company Business Wire release, 2025-05-14, syndicated copy](https://markets.financialcontent.com/spoke/article/bizwire-2025-5-14-turbineone-raises-36m-series-b-to-deploy-ai-at-the-tactical-edge ); [Axios newsletter, 2025-05-14](https://www.axios.com/newsletters/axios-future-of-defense-eb862a80-2b4d-11f0-b2f6-454e7562db1d ). | Direct firm attribution is explicit, and the corrected release is preferred over conflicting lead-investor summaries. USD 36 million is the entire financing, not TheGP's check. Official case-study partnership dates include operational/incubation activity, which should not be fabricated into a priced round. No neural interface or neurotech application established. | SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
General Catalyst
Manas$24M · 2025-09-24
Thatch$40M · 2025-04-03
Aven$— · 2024-07-17
Collective$50M · 2023-07-11
Thatch Health$40M · Unknown date
Dynaboard$6M · Unknown date
Y Combinator
Ultralight$9M · 2026-04-13
Minerva$20M · Unknown date
Momento$15M · Unknown date
Gradient Ventures
HOF Capital
Cassidy AI$10M · 2025-09-08
Lightspeed
Finix$30M · 2022-08-10
Multiplier Holdings$35M · Unknown date
Sequoia
Switchboard$13M · 2022-05-02
Stainless$25M · Unknown date
Alex Immerman
Sardine$52M · 2022-09-20
Andreessen Horowitz
Angela Strange
Bessemer Venture Partners
TurbineOne$— · 2025
Darian Shirazi
Eric Schmidt
Inovia Capital
Niko Bonatsos
Peter Levine
Graphite$52M · 2025-03-18
Rama Sekhar
